Boston Scientific revenue and financials

BSX · NYSE · USD

$42.28Change from previous close: +0.20%Absolute change: +$0.09

Close · October 7, 2026

In the fiscal year ended December 2025, Boston Scientific reported revenue of $20.07B (+19.87% year over year). Net income was $2.89B, a net margin of 14.4%.

Annual revenue · 2025: $20.07B
  1. $9.08B2016
  2. $9.05B2017
  3. $9.82B2018
  4. $10.74B2019
  5. $9.91B2020
  6. $11.89B2021
  7. $12.68B2022
  8. $14.24B2023
  9. $16.75B2024
  10. $20.07B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+19.87%
2025 vs 2024
Net income growth
+56.66%
2025 vs 2024
Net margin
14.4%
2024: 11.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Annual
Item2025202420232022202120202019201820172016
Total assets43,67339,39535,13632,46932,22930,77730,56520,99919,04218,096
Current assets8,7946,9206,5145,7606,3176,6944,6994,0033,8223,239
Cash and equivalents1,9654148659281,9251,734217146188196
Receivables2,9262,5582,2281,9701,778—————
Inventory2,9432,8102,4841,8671,610—————
Net property, plant and equipment4,5013,7433,2982,8322,687—————
Goodwill18,28217,08914,38712,92011,9889,95110,1767,9116,9986,678
Other intangible assets7,0196,6846,0035,9696,235—————
Long-term investments682555413407411—————
Current liabilities5,4396,3994,9333,8034,2743,6814,8665,2605,6543,587
Accounts payable1,144960942862794—————
Long-term debt11,13710,7469,1028,9359,0659,14310,0087,0563,8155,400
Total debt11,43610,7469,4929,282——————
Total liabilities19,20117,39215,60614,89615,607—————
Total equity (incl. minority)24,47222,00319,53017,57316,622—————
Retained earnings5,5712,673819-750-1,392—————
Minority interest2392332480.0——————